COSMOS Pharmaceutical Corporation

Equities

3349

JP3298400007

Drug Retailers

Market Closed - Japan Exchange 02:00:00 2024-04-25 am EDT 5-day change 1st Jan Change
14,505 JPY +0.62% Intraday chart for COSMOS Pharmaceutical Corporation -1.76% -10.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cosmos Pharmaceutical's Attributable Profit Up 6.6% in Fiscal Nine Months MT
COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 CI
Cosmos Pharmaceutical’s Attributable Profit Up 2.6% in Fiscal H1 on Expansion of Stores MT
COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024 CI
COSMOS Pharmaceutical Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending May 31, 2024, Payable on February 13, 2024; Provides Year Dividend Guidance for fiscal Year Ending May 31, 2024 CI
Cosmos Pharmaceutical’s Attributable Profit up marginally by 0.4% in Fiscal Q1 After Opening New Stores MT
COSMOS Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended August 31, 2023 CI
COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024 CI
Cosmos Attributable Profit Increases 2.8% in Fiscal Year 2023 MT
COSMOS Pharmaceutical Corporation Announces Year-End Dividend for the Year Ended May 31, 2023, Payable on August 3, 2023; Provides Dividend Guidance for the Second Quarter-End and Full Year of Full Year Ending May 31, 2024 CI
COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024 CI
Cosmos Pharma's Attributable Profit Slides 1% in Fiscal Nine Months Amid New Store Openings MT
COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2023 CI
COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal year ending May 31, 2023 CI
Cosmos Pharma Books Marginal Rise in Fiscal H1 Attributable Profit Amid New Store Openings, Low-cost Strategy MT
COSMOS Pharmaceutical Corporation Announces Dividend for the Second Quarter of Fiscal 2023; Provides Dividend Guidance for the Full Year of Fiscal Year Ending May 31, 2023 CI
Cosmos Pharmaceutical Corporation Provides Earnings Forecast for the Fiscal Year Ending May 31, 2023 CI
Cosmos Pharma Clocks Higher Profit, Revenue in Fiscal Q1 on New Store Openings MT
COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Second Quarter-End and Full Year of Fiscal Year Ending May 31, 2023 CI
UBS Adjusts COSMOS Pharmaceutical’s Price Target to 15,500 Yen From 16,500 Yen, Keeps at Neutral MT
Cosmos Pharmaceutical Logs Lower Profit in FY22 Despite Jump in Net Sales; Shares Climb 6% MT
COSMOS Pharmaceutical Corporation Announces Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending May 31, 2023 CI
UBS Adjusts Cosmos Pharmaceutical's Price Target to 16,500 Yen From 17,500 Yen, Keeps at Neutral MT
Global markets live: Baidu, Cisco, Nvidia, Amazon, Apple... Our Logo
COSMOS Pharmaceutical : Topix closes at near one-month high as investors await earnings RE
Chart COSMOS Pharmaceutical Corporation
More charts
COSMOS Pharmaceutical Corporation is a company primarily engaged in the operation of drug stores. The Company offers medical goods, including general self-medication products, tonic drinks, oral care products, nursing care products, vitamin supplements, health food products, diet food and dispensing. Cosmetic products include cosmetic products for women and men, hair care products and bath agents. Miscellaneous goods include baby goods, detergents, insecticides, deodorizers, bath goods, toiletries, cookware, gardening goods, automobile goods and clothing products. General food products include processed food products, daily food products, seasonings, confectionery, non-alcoholic beverages and alcoholic beverages. It also provides tobacco and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
14,505 JPY
Average target price
16,620 JPY
Spread / Average Target
+14.58%
Consensus
  1. Stock Market
  2. Equities
  3. 3349 Stock
  4. News COSMOS Pharmaceutical Corporation
  5. Cosmos Pharmaceutical Logs Lower Profit in FY22 Despite Jump in Net Sales; Shares Climb 6%